Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Follow-Up Questions
What is Arcus Biosciences Inc (RCUS)'s P/E Ratio?
The P/E ratio of Arcus Biosciences Inc is N/A
Who is the CEO of Arcus Biosciences Inc?
Dr. Terry Rosen is the Chairman of the Board of Arcus Biosciences Inc, joining the firm since 2015.
What is the price performance of RCUS stock?
The current price of RCUS is 12.44, it has increased 0.04% in the last trading day.
What are the primary business themes or industries for Arcus Biosciences Inc?
Arcus Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Arcus Biosciences Inc market cap?
Arcus Biosciences Inc's current market cap is $1.3
Is Arcus Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Arcus Biosciences Inc, including 5 strong buy, 11 buy, 3 hold, 0 sell, and 5 strong sell
